Business News • PR NewsWire • CORRECTION - APAC Biotech Pvt. Ltd: Indian FDA Approves the First Autologous Dendritic Cell-based Immuno-oncology Product, APCEDEN®

CORRECTION - APAC Biotech Pvt. Ltd: Indian FDA Approves the First Autologous Dendritic Cell-based Immuno-oncology Product, APCEDEN®

CORRECTION - APAC Biotech Pvt. Ltd: Indian FDA Approves the First Autologous Dendritic Cell-based Immuno-oncology Product, APCEDEN®

A first-of-its-kind Indian biotechnology company, APAC Biotech, was granted with a commercial license by Indian FDA (CDSCO - Central Drugs Standard Control Organization) to market product, APCEDEN®, a Dendritic cell-based autologous Immuno-oncology product for four cancer indication...

View More : http://www.prnewswire.com/news-releases/correction---apac-biotech-pvt-ltd-indian-fda-approves-the-first-autologous-dendr...

Releted News by prnewswire

Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago® (safinamide) in Canada

Global Sources Electronics show opens today with 6,200 booths in two phases